Skip to main content

Idiopathic Subglottic Stenosis (iSGS)

0
Pipeline Programs
6
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

6 companies ranked by most advanced pipeline stage

Airway Therapeutics
Airway TherapeuticsGA - Marietta
1 program
Endoscopic dilation of subglottic stenosisN/A
Colorado Therapeutics
Colorado TherapeuticsCO - Louisville
1 program
Endoscopic dilation of subglottic stenosisN/A
Utah Medical
Utah MedicalIreland - Dublin
1 program
Endoscopic dilation of subglottic stenosisN/A
Angeles Therapeutics
Angeles TherapeuticsCA - Los Angeles
1 program
Endoscopic dilation of subglottic stenosisN/A1 trial
Active Trials
NCT02481817Completed1,239Est. Sep 2020
Oregon Therapeutics
Oregon TherapeuticsFrance - Paris
1 program
Endoscopic dilation of subglottic stenosisN/A
Temple Therapeutics
Temple TherapeuticsNetherlands - Geleen
1 program
Endoscopic dilation of subglottic stenosisN/A

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Angeles TherapeuticsEndoscopic dilation of subglottic stenosis

Clinical Trials (1)

Total enrollment: 1,239 patients across 1 trials

NCT02481817Angeles TherapeuticsEndoscopic dilation of subglottic stenosis

Treatment Alternatives in iSGS (NoAAC PR-02 Study)

Start: Aug 2015Est. completion: Sep 20201,239 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

6 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.